Seek Returns logo

ABBV vs. CNC: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ABBV and CNC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

SymbolABBVCNC
Company NameAbbVie Inc.Centene Corporation
CountryUnited StatesUnited States
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyHealth Care Providers & Services
Market Capitalization355.91 billion USD13.29 billion USD
ExchangeNYSENYSE
Listing DateJanuary 2, 2013December 13, 2001
Security TypeCommon StockCommon Stock

Historical Performance

This chart compares the performance of ABBV and CNC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ABBV vs. CNC: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolABBVCNC
5-Day Price Return1.31%7.17%
13-Week Price Return6.00%-56.94%
26-Week Price Return4.40%-53.83%
52-Week Price Return5.94%-64.23%
Month-to-Date Return6.59%3.84%
Year-to-Date Return13.38%-55.32%
10-Day Avg. Volume5.23M15.77M
3-Month Avg. Volume6.91M11.24M
3-Month Volatility23.63%88.86%
Beta0.490.43

Profitability

Return on Equity (TTM)

ABBV

95.59%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

ABBV’s Return on Equity of 95.59% is exceptionally high, placing it well beyond the typical range for the Biotechnology industry. This demonstrates a superior ability to generate profit from shareholder investments, though it could also be inflated by high financial leverage.

CNC

7.53%

Health Care Providers & Services Industry

Max
26.03%
Q3
13.74%
Median
8.26%
Q1
4.13%
Min
-3.62%

CNC’s Return on Equity of 7.53% is on par with the norm for the Health Care Providers & Services industry, indicating its profitability relative to shareholder equity is typical for the sector.

ABBV vs. CNC: A comparison of their Return on Equity (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Net Profit Margin (TTM)

ABBV

6.45%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

ABBV’s Net Profit Margin of 6.45% is aligned with the median group of its peers in the Biotechnology industry. This indicates its ability to convert revenue into profit is typical for the sector.

CNC

1.15%

Health Care Providers & Services Industry

Max
12.40%
Q3
5.93%
Median
1.96%
Q1
0.93%
Min
-6.10%

CNC’s Net Profit Margin of 1.15% is aligned with the median group of its peers in the Health Care Providers & Services industry. This indicates its ability to convert revenue into profit is typical for the sector.

ABBV vs. CNC: A comparison of their Net Profit Margin (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Operating Profit Margin (TTM)

ABBV

18.80%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

ABBV’s Operating Profit Margin of 18.80% is around the midpoint for the Biotechnology industry, indicating that its efficiency in managing core business operations is typical for the sector.

CNC

1.08%

Health Care Providers & Services Industry

Max
19.05%
Q3
10.21%
Median
4.22%
Q1
1.98%
Min
-4.27%

CNC’s Operating Profit Margin of 1.08% is in the lower quartile for the Health Care Providers & Services industry. This indicates weaker profitability from core operations, which may stem from inefficiencies or competitive pressures on pricing.

ABBV vs. CNC: A comparison of their Operating Profit Margin (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Profitability at a Glance

SymbolABBVCNC
Return on Equity (TTM)95.59%7.53%
Return on Assets (TTM)2.73%2.43%
Net Profit Margin (TTM)6.45%1.15%
Operating Profit Margin (TTM)18.80%1.08%
Gross Profit Margin (TTM)70.93%8.93%

Financial Strength

Current Ratio (MRQ)

ABBV

0.74

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

ABBV’s Current Ratio of 0.74 is notably low, falling beneath the typical range for the Biotechnology industry. This suggests a heightened liquidity risk and could indicate potential challenges in meeting its short-term obligations.

CNC

1.10

Health Care Providers & Services Industry

Max
2.01
Q3
1.49
Median
1.30
Q1
0.94
Min
0.17

CNC’s Current Ratio of 1.10 aligns with the median group of the Health Care Providers & Services industry, indicating that its short-term liquidity is in line with its sector peers.

ABBV vs. CNC: A comparison of their Current Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Debt-to-Equity Ratio (MRQ)

ABBV

49.22

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

With a Debt-to-Equity Ratio of 49.22, ABBV operates with exceptionally high leverage compared to the Biotechnology industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.

CNC

0.64

Health Care Providers & Services Industry

Max
2.17
Q3
1.18
Median
0.74
Q1
0.45
Min
0.00

CNC’s Debt-to-Equity Ratio of 0.64 is typical for the Health Care Providers & Services industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ABBV vs. CNC: A comparison of their Debt-to-Equity Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Interest Coverage Ratio (TTM)

ABBV

2.70

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

ABBV’s Interest Coverage Ratio of 2.70 is in the upper quartile for the Biotechnology industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.

CNC

7.06

Health Care Providers & Services Industry

Max
14.47
Q3
7.15
Median
5.45
Q1
2.04
Min
-4.44

CNC’s Interest Coverage Ratio of 7.06 is positioned comfortably within the norm for the Health Care Providers & Services industry, indicating a standard and healthy capacity to cover its interest payments.

ABBV vs. CNC: A comparison of their Interest Coverage Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Financial Strength at a Glance

SymbolABBVCNC
Current Ratio (MRQ)0.741.10
Quick Ratio (MRQ)0.481.10
Debt-to-Equity Ratio (MRQ)49.220.64
Interest Coverage Ratio (TTM)2.707.06

Growth

Revenue Growth

ABBV vs. CNC: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ABBV vs. CNC: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ABBV

3.23%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ABBV’s Dividend Yield of 3.23% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.

CNC

0.00%

Health Care Providers & Services Industry

Max
5.38%
Q3
2.22%
Median
0.55%
Q1
0.00%
Min
0.00%

CNC currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ABBV vs. CNC: A comparison of their Dividend Yield (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Dividend Payout Ratio (TTM)

ABBV

226.84%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 226.84%, ABBV’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

CNC

0.00%

Health Care Providers & Services Industry

Max
186.69%
Q3
74.82%
Median
26.76%
Q1
0.00%
Min
0.00%

CNC has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

ABBV vs. CNC: A comparison of their Dividend Payout Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Dividend at a Glance

SymbolABBVCNC
Dividend Yield (TTM)3.23%0.00%
Dividend Payout Ratio (TTM)226.84%0.00%

Valuation

Price-to-Earnings Ratio (TTM)

ABBV

93.25

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

At 93.25, ABBV’s P/E Ratio is exceptionally high, exceeding the typical maximum for the Biotechnology industry. This suggests the stock may be significantly overvalued compared to its peers and implies high market expectations that could be difficult to meet.

CNC

6.43

Health Care Providers & Services Industry

Max
55.89
Q3
30.85
Median
21.17
Q1
12.63
Min
0.00

In the lower quartile for the Health Care Providers & Services industry, CNC’s P/E Ratio of 6.43 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.

ABBV vs. CNC: A comparison of their Price-to-Earnings Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Price-to-Sales Ratio (TTM)

ABBV

6.02

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

ABBV’s P/S Ratio of 6.02 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

CNC

0.07

Health Care Providers & Services Industry

Max
3.10
Q3
1.74
Median
0.67
Q1
0.24
Min
0.00

In the lower quartile for the Health Care Providers & Services industry, CNC’s P/S Ratio of 0.07 indicates its revenue is valued more conservatively than most of its peers. This could present a compelling opportunity if the market has overlooked its sales-generating capabilities.

ABBV vs. CNC: A comparison of their Price-to-Sales Ratio (TTM) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Price-to-Book Ratio (MRQ)

ABBV

261.01

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

At 261.01, ABBV’s P/B Ratio is at an extreme premium to the Biotechnology industry. This signifies that the market’s valuation is heavily reliant on future potential rather than its current net asset value, which can be a high-risk proposition.

CNC

0.99

Health Care Providers & Services Industry

Max
7.61
Q3
4.32
Median
2.53
Q1
1.14
Min
0.77

CNC’s P/B Ratio of 0.99 is in the lower quartile for the Health Care Providers & Services industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ABBV vs. CNC: A comparison of their Price-to-Book Ratio (MRQ) against their respective Biotechnology and Health Care Providers & Services industry benchmarks.

Valuation at a Glance

SymbolABBVCNC
Price-to-Earnings Ratio (TTM)93.256.43
Price-to-Sales Ratio (TTM)6.020.07
Price-to-Book Ratio (MRQ)261.010.99
Price-to-Free Cash Flow Ratio (TTM)19.244.48